CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Standard Donor PlasmaWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)

Name (Synonyms) Correlation
drug647 Convalescent Plasma Wiki 0.22
drug1978 Questionnaire Wiki 0.21

Correlated MeSH Terms (2)

Name (Synonyms) Correlation
D002055 Burnout, Professional NIH 0.45
D000077062 Burnout, Psychological NIH 0.30

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 Convalescent Plasma to Reduce Complications Associated With COVID-19 Infection: A Randomized Trial Comparing the Efficacy and Safety of High-Titer Anti-SARS-CoV-2 Plasma vs. Standard Plasma in Hospitalized Patients With COVID- 19 Infection

The purpose of this study is to find out if transfusion of blood plasma containing antibodies against COVID-19 (anti-SARS-CoV-2), which were donated from a patient who recovered from COVID-19 infection, is safe and can treat COVID-19 in hospitalized patients. Antibodies are blood proteins produced by the body in response to a virus and can remain in the person's bloodstream (plasma) for a long time after they recover. Transferring plasma from a person who recovered from COVID-19 may help neutralize the virus in sick patients' blood, and/or reduce the chances of the infection getting worse.

NCT04344535 COVID Biological: Convalescent Plasma Biological: Standard Donor Plasma

Primary Outcomes

Description: Number of days a patient is receiving mechanical invasive ventilation through 28 days post randomization. Patients who die during this time period are assigned 0 ventilator free days.

Measure: 28 day ventilator free days

Time: 28 days post randomization

Secondary Outcomes

Description: All cause mortality from randomization until 90 days post randomization

Measure: 90 day all-cause mortality

Time: 90 days

No related HPO nodes (Using clinical trials)